Cell Therapy Firm Kyverna Eyes $200M IPO As Pipeline Builds
Autoimmune diseases-focused drug developer Kyverna Therapeutics Inc. on Thursday unveiled a price range for an estimated $200 million initial public offering, guided by Paul Hastings LLP and underwriters counsel Covington &...To view the full article, register now.
Already a subscriber? Click here to view full article